Effect of Fluoxetine on Carvedilol Pharmacokinetics, CYP2D6 Activity, and Autonomic Balance in Heart Failure Patients
- 1 January 2001
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 41 (1), 97-106
- https://doi.org/10.1177/00912700122009746
Abstract
The objective of this study was to examine the pharmacokinetic and pharmacodynamic consequences of concomitant administration of fluoxetine and carvedilol in heart failure patients. Fluoxetine (20 mg) or matching placebo was administered in a randomized, double‐blind, two‐period crossover study to 10 patients previously identified as extensive metabolizers of CYP2D6 substrates. Patients were maintained on a carvedilol dose of 25 or 50 mg bid and given fluoxetine/placebo for a minimum of 28 days. Plasma was collected over the 12‐hour carvedilol dosing interval, and the concentrations of the R(+) and S(−) enantiomers of carvedilol were measured. CYP2D6 phenotype was assessed during each study period using dextromethorphan (30 mg). Changes in autonomic modulation between study periods were measured by heart rate variability in the time and frequency domains using ambulatory electrocardiographic monitoring. Compared to placebo, fluoxetine coadministration resulted in a 77% increase in mean (± SD) R(+) enantiomer AUC0–12 (522 ± 413 vs. 927 ± 506 ng•h/mL, p = 0.01) and a nonsignificant increase in S(−) enantiomer AUC (244 ± 185 vs. 330 ±179 ng•h/mL, p = 0.17). Mean apparent oral clearance for both enantiomers decreased significantly with fluoxetine administration (R(+): 10.3 ± 7.2 vs. 4.5 ± 2.2 mL/min/kg; S(−): 22.5 ± 12.3 vs. 12.6 ± 7.4 mL/min/kg; p = 0.004 and 0.03, respectively). No differences in adverse effects, blood pressure, or heart rate were noted between treatment groups, and there were no consistent changes in heart rate variability parameters. In conclusion, fluoxetine administration resulted in a stereospecific inhibition of carvedilol metabolism, with the R(+) enantiomer increasing to a greater extent than the S(−) enantiomer. However, this interaction was of little clinical significance in our sample population.Keywords
This publication has 38 references indexed in Scilit:
- HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approachesJournal of Cardiac Failure, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Effects of bisoprolol on heart rate variability in heart failureThe American Journal of Cardiology, 1996
- Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patientsPharmacological Research, 1995
- Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infarctionThe American Journal of Cardiology, 1994
- Assay and Disposition of Carvedilol Enantiomers in Humans and Monkeys: Evidence of Stereoselective Presystemic MetabolismJournal of Pharmaceutical Sciences, 1990
- Simultaneous Determination of Dextromethorphan and Three Metabolites in Plasma and Urine Using High-Performance Liquid Chromatography with Application to Their Disposition in ManTherapeutic Drug Monitoring, 1990
- Fluoxetine treatment of depressionActa Psychiatrica Scandinavica, 1989
- Decreased heart rate variability and its association with increased mortality after acute myocardial infarctionThe American Journal of Cardiology, 1987
- High‐Performance Liquid Chromatographic Assay for Imipramine, Desipramine, and Their 2‐Hydroxylated MetabolitesJournal of Pharmaceutical Sciences, 1979